• Loading stock data…

MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting

[#item_full_content]

Print Friendly, PDF & Email
Spread the word